Cefadroxil as Oral Transitional Therapy for Gram-Positive Bacteremia With or Without Non-Vertebral Osteomyelitis: A Multicenter Retrospective Cohort Study
Abstract
Background: Oral cefadroxil has favorable pharmacokinetics for the treatment of bloodstream infection (BSI) and osteomyelitis caused by Gram-positive cocci (GPC), but limited clinical data exist.
Methods: We conducted a multicenter, retrospective cohort study between September 2022 and April 2025 assessing cefadroxil versus intravenous (IV)-only or other oral transitional therapy in adults with susceptible GPC BSI, with or without osteomyelitis. No patients with endocarditis, vertebral osteomyelitis, or prosthetic or central nervous system infections were included. Primary outcome was treatment success, defined as 90-day survival without infection progression or relapse. Prioritized secondary outcomes included all-cause mortality, recurrent bacteremia, and readmission at 90 days.
Results: Of 323 patients with BSI, 58 were treated with cefadroxil, 72 IV only, and 193 with other oral antibiotics. Rates of osteomyelitis were comparable in each cohort, but skin and soft-tissue infections were a more common source of bacteremia in cefadroxil (52%) than either IV (28%, P = .01) or orally (PO) (31%, P = .003) cohorts. Staphylococcus aureus was more frequent in the IV (60%) than cefadroxil cohort (36%, P = .008). Nevertheless, cefadroxil-treated patients had a similar case mix index, expected mortality, and expected length of stay as the IV and PO cohorts, indicating comparable populations. Treatment success was similar for cefadroxil (91%), IV (94%, P = .51), and other oral (93%, P…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 323 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.